Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03862157CT.gov Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Eosinophilic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pevonedistat (this asset) | M.D. Anderson Cancer Center | P1/2 | CCC · 48 |
| Calcium Phosphate | Children's Oncology Group | P3 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Busulfanum | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Ondansetron | Fred Hutchinson Cancer Center | P2 | B |
| Cyclophosphamide | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Fludarabine | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | B |
| Propaderm Forte | Fred Hutchinson Cancer Center | P2 | B |
| Methotrexate | Fred Hutchinson Cancer Center | P2 | CCC |
+18 more in the Chronic Eosinophilic Leukemia cohort
Other indications for Pevonedistat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Myelomonocytic Leukemia | — | P3 | BB · 70 |
| Acute Myeloid Leukemia | — | P3 | BB · 66 |
| Myelodysplastic Syndrome | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Calcium PhosphateChildren's Oncology GroupBB
- TacrolimusSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityB
- BusulfanumSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityB
- OndansetronFred Hutchinson Cancer CenterB
- CyclophosphamideSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityB
Citation
Floatz Terminal. Pevonedistat in Chronic Eosinophilic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pevonedistat-chronic-eosinophilic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →